NCT03352427

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR Alterations

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: University of Michigan Rogel Cancer Center · Academic / Other
• Sex: All
• Age: 1 Year – 50 Years
• Healthy volunteers: Not accepted

Summary

This trial will evaluate the activity of dasatinib in combination with everolimus for children with gliomas harboring PDGFR alterations, including newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) after radiation (stratum A); and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).

Conditions

• Glioma
• High Grade Glioma
• Pontine Tumors

Interventions

Type	Name	Description
DRUG	Dasatinib	60 mg/m2 orally twice daily
DRUG	Everolimus	3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml

Timeline

• Start date: 2017-12-06
• Primary completion: 2019-04-17
• Completion: 2019-05-15
• First posted: 2017-11-24
• Last updated: 2022-10-05
• Results posted: 2022-10-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study